Volume 5, Issue 2 (Summer-Fall 2022)
Mod Med Lab J 2022, 5(2): 38-46 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghashghaei S, Mousavi M A, Karimi S, Nadali Pour S S, Nabavi S M, Vosough M. Advanced therapeutic medicinal products (ATMPs) in Ischemic Stroke; novel therapeutic modalities from financial perspective. Mod Med Lab J 2022; 5 (2) :38-46
URL: http://modernmedlab.com/article-1-118-en.html
URL: http://modernmedlab.com/article-1-118-en.html
Shahriar Ghashghaei 
, Maryam Alsadat Mousavi , Shahedeh Karimi , Seyed Sam Nadali Pour , Seyed Massood Nabavi , Massoud Vosough
, Maryam Alsadat Mousavi , Shahedeh Karimi , Seyed Sam Nadali Pour , Seyed Massood Nabavi , Massoud Vosough
Abstract: (1343 Views)
Stroke, is accounting for more than 34% of total healthcare spending globally. Ischemic stroke (IS) accounts for 62.4% of incident stroke cases. IS-related direct medical expenditures place a considerable burden on healthcare system. The burden is more prominent in developing countries where limitations in insurance coverage is a big concern. It would be less challenging in developed countries, where costs are covered by third parties.
After introduction of advanced therapeutic medicinal products (ATMPs), a new line of treatments is proposed. Although the high prices of these treatments may cause financial concerns, they have encouraged scientists and provided acceptable results in a way that makes investment in this area reasonable for health experts. All ATMP-based therapies used in clinical trials for the treatment of IS are stem-cell-based or stem-cell-derivatives. The cost of stem-cell-based therapies are considerable like other alternative medical settings, e.g., thrombolysis and thrombectomy. However, the considerable recovery after prescription of ATMPs is expected to be cost-effective. Furthermore, various gene therapy approaches for the treatment of IS have been proposed. However, none has been qualified for clinical studies yet. If such a procedure is introduced in near future, it does not necessarily guarantee that these innovative treatments would be offered to the patients. Application of ATMPs have many challenges particularly in developing countries. This is primarily related to exorbitant expenditures. Despite these challenges, the insurance systems in developed-countries supports stem-cell therapies as novel treatments. Significant improvements in the insurance systems of both developing and developed countries are necessary.
After introduction of advanced therapeutic medicinal products (ATMPs), a new line of treatments is proposed. Although the high prices of these treatments may cause financial concerns, they have encouraged scientists and provided acceptable results in a way that makes investment in this area reasonable for health experts. All ATMP-based therapies used in clinical trials for the treatment of IS are stem-cell-based or stem-cell-derivatives. The cost of stem-cell-based therapies are considerable like other alternative medical settings, e.g., thrombolysis and thrombectomy. However, the considerable recovery after prescription of ATMPs is expected to be cost-effective. Furthermore, various gene therapy approaches for the treatment of IS have been proposed. However, none has been qualified for clinical studies yet. If such a procedure is introduced in near future, it does not necessarily guarantee that these innovative treatments would be offered to the patients. Application of ATMPs have many challenges particularly in developing countries. This is primarily related to exorbitant expenditures. Despite these challenges, the insurance systems in developed-countries supports stem-cell therapies as novel treatments. Significant improvements in the insurance systems of both developing and developed countries are necessary.
Keywords: Advanced therapeutic medicinal products (ATMPs), Ischemic stroke, Insurance systems, Developing countries
Type of Study: Review Article |
Subject:
Stem Cell and Regenerative Medicine
References
1. The top 10 causes of death: World Health Organization; 2020 [cited 2022 January 16]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
2. De la Fuente-Martínez J, Infante-Valenzuela A, Martínez-Roque D, Cruz-Moreno M, Góngora-Rivera F. Impact of Arrhythmia in Hospital Mortality in Acute Ischemic Stroke Patients: A Retrospective Cohort Study in Northern Mexico. Journal of Stroke and Cerebrovascular Diseases. 2022;31(2):106259.
3. Rochmah TN, Rahmawati IT, Dahlui M, Budiarto W, Bilqis N. Economic Burden of Stroke Disease: A Systematic Review. International journal of environmental research and public health. 2021;18(14):7552.
4. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e733-e6.
5. Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, et al. US health care spending by payer and health condition, 1996-2016. Jama. 2020;323(9):863-84.
6. Movahed MS, Barghazan SH, Adel A, Rezapour A. Economic Burden of Stroke in Iran: A Population-Based Study. Value in Health Regional Issues. 2021;24:77-81.
7. Maryam Rahbari MBA-a, Sadegh Ghazanfari, Ali Akhavan Behbahani, Muhammad Reza Maleki. 2018 national budget. In: congress Rco, editor. rc.majlis.ir: Research center of congress; 2017.
8. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology. 2021;20(10):795-820.
9. Kaur P, Kwatra G, Kaur R, Pandian JD. Cost of stroke in low and middle income countries: a systematic review. International Journal of Stroke. 2014;9(6):678-82.
10. Joo H, Wang G, George MG. A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischaemic stroke. Stroke and vascular neurology. 2017;2(2).
11. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418.
12. Teljeur C, Harrington P, Glynn RW, Ryan M. Acute ischaemic stroke: a systematic review of the cost-effectiveness of emergency endovascular therapy using mechanical thrombectomy. Irish Journal of Medical Science (1971-). 2019;188(3):751-9.
13. Barbosa E, Gulela B, Taimo MA, Lopes DM, Offorjebe OA, Risko N. A systematic review of the cost-effectiveness of emergency interventions for stroke in low-and middle-income countries. African Journal of Emergency Medicine. 2020;10:S90-S4.
14. Van Roijen L, Koopmanschap MA, Rutten FF, Van der Maas PJ. Indirect costs of disease; an international comparison. Health Policy. 1995;33(1):15-29.
15. Lloyd‐Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. British journal of clinical pharmacology. 2021;87(6):2428-43.
16. Webster I. Inflation Calculator [cited 2022 January 16]. Available from: https://www.officialdata.org/us/inflation/.
17. Sundar K, Panwar A, Yagaval DR, Huded V, Sylaja P. Mission thrombectomy 2020 (MT2020)—India’s biggest healthcare challenge yet. Journal of Stroke Medicine. 2020;3(2):62-71.
18. Pan Y, Cai X, Huo X, Zhao X, Liu L, Wang Y, et al. Cost-effectiveness of mechanical thrombectomy within 6 hours of acute ischaemic stroke in China. BMJ open. 2018;8(2):e018951.
19. Tsang ACO, Yang I-H, Orru E, Nguyen Q-A, Pamatmat RV, Medhi G, et al. Overview of endovascular thrombectomy accessibility gap for acute ischemic stroke in Asia: a multi-national survey. International Journal of Stroke. 2020;15(5):516-20.
20. Amiri A, Goudarzi R, Amiresmaili M, Iranmanesh F. Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran. Journal of medical economics. 2018;21(3):282-7.
21. Pan Y, Chen Q, Zhao X, Liao X, Wang C, Du W, et al. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China. PLoS One. 2014;9(10):e110525.
22. Ghandehari K, Zahed AP, Taheri M, Abbasi M, Gorjestani S, Ahmadi AM, et al. Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA. International Journal of Stroke. 2009;4(4):236-.
23. Yang Y, Man X, Nicholas S, Li S, Bai Q, Huang L, et al. Utilisation of health services among urban patients who had an ischaemic stroke with different health insurance-a cross-sectional study in China. BMJ open. 2020;10(10):e040437.
24. Zhang H, Yin Y, Zhang C, Zhang D. Costs of hospitalization for stroke from two urban health insurance claims data in Guangzhou City, southern China. BMC health services research. 2019;19(1):1-12.
25. Yin X, Huang L, Man X, Jiang Y, Zhao X, Zhao L, et al. Inpatient cost of stroke in Beijing: a descriptive analysis. Neuroepidemiology. 2018;51(3-4):115-22.
26. Chhabra M, Sharma A, Ajay KR, Rathore MS. Assessment of risk factors, cost of treatment, and therapy outcome in stroke patients: evidence from cross-sectional study. Expert review of pharmacoeconomics & outcomes research. 2019;19(5):575-80.
27. Abdo RR, Abboud HM, Salameh PG, Jomaa NA, Rizk RG, Hosseini HH. Direct medical cost of hospitalization for acute stroke in Lebanon: a prospective incidence-based multicenter cost-of-Illness study. INQUIRY: The Journal of Health Care Organization, Provision, and Financing. 2018;55:0046958018792975.
28. Heeley E, Anderson CS, Huang Y, Jan S, Li Y, Liu M, et al. Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke. 2009;40(6):2149-56.
29. Dirks M, Baeten SA, Dippel DW, Van Exel NJA, Van Wijngaarden JD, Huijsman R, et al. Real-life costs and effects of an implementation program to increase thrombolysis in stroke. Neurology. 2012;79(6):508-14.
30. Liu Y, Wang Z, Haimei Q. The cost-effectiveness of stroke rehabilitation care: a systematic review of randomized controlled trails studies. Chinese Journal of Geriatrics. 2018;37(6):702-6.
31. Bernhardt J, Urimubenshi G, Gandhi DB, Eng JJ. Stroke rehabilitation in low-income and middle-income countries: a call to action. The Lancet. 2020;396(10260):1452-62.
32. Medford‐Davis LN, Fonarow GC, Bhatt DL, Xu H, Smith EE, Suter R, et al. Impact of insurance status on outcomes and use of Rehabilitation Services in acute ischemic stroke: findings from get with the guidelines‐stroke. Journal of the American Heart Association. 2016;5(11):e004282.
33. Bouvy J, Fransen P, Baeten S, Koopmanschap M, Niessen LW, Dippel D. Cost‐effectiveness of two endovascular treatment strategies vs intravenous thrombolysis. Acta Neurologica Scandinavica. 2013;127(5):351-9.
34. Mangla S, O'Connell K, Kumari D, Shahrzad M. Novel model of direct and indirect cost–benefit analysis of mechanical embolectomy over IV tPA for large vessel occlusions: a real-world dollar analysis based on improvements in mRS. Journal of neurointerventional surgery. 2016;8(12):1312-6.
35. Pizzo E, Dumba M, Lobotesis K. Cost-utility analysis of mechanical thrombectomy between 6 and 24 hours in acute ischemic stroke. International Journal of Stroke. 2020;15(1):75-84.
36. Rajsic S, Gothe H, Borba H, Sroczynski G, Vujicic J, Toell T, et al. Economic burden of stroke: a systematic review on post-stroke care. The European Journal of Health Economics. 2019;20(1):107-34.
37. Ridic G, Gleason S, Ridic O. Comparisons of health care systems in the United States, Germany and Canada. Materia socio-medica. 2012;24(2):112.
38. Brady BK, McGahan L, Skidmore B. Systematic review of economic evidence on stroke rehabilitation services. International journal of technology assessment in health care. 2005;21(1):15-21.
39. Norrving B, Barrick J, Davalos A, Dichgans M, Cordonnier C, Guekht A, et al. Action plan for stroke in Europe 2018–2030. European Stroke Journal. 2018;3(4):309-36.
40. Tung Y-J, Lin W-C, Lee L-F, Lin H-M, Ho C-H, Chou W. Comparison of Cost-Effectiveness between Inpatient and Home-Based Post-Acute Care Models for Stroke Rehabilitation in Taiwan. International Journal of Environmental Research and Public Health. 2021;18(8):4129.
41. Cramer SC, Dodakian L, Le V, See J, Augsburger R, McKenzie A, et al. Efficacy of home-based telerehabilitation vs in-clinic therapy for adults after stroke: a randomized clinical trial. JAMA neurology. 2019;76(9):1079-87.
42. Leng T, Xiong Z-G. Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges. Brain circulation. 2019;5(1):8.
43. Lin L, Hu K. Tissue plasminogen activator: side effects and signaling. Journal of drug design and research. 2014;1(1).
44. Jadhav AP, Desai SM, Kenmuir CL, Rocha M, Starr MT, Molyneaux BJ, et al. Eligibility for endovascular trial enrollment in the 6-to 24-hour time window: analysis of a single comprehensive stroke center. Stroke. 2018;49(4):1015-7.
45. Kurre W, Bäzner H, Henkes H. Mechanische Thrombektomie: Akutkomplikationen und Spätfolgen (Leitthema). Der Radiologe. 2016;56(1):32-41.
46. Chumnanvej S, Chumnanvej S. Autologous bone-marrow mononuclear stem cell therapy in patients with stroke: a meta-analysis of comparative studies. BioMedical Engineering OnLine. 2020;19(1):1-13.
47. Suda S, Nito C, Yokobori S, Sakamoto Y, Nakajima M, Sowa K, et al. Recent advances in cell-based therapies for ischemic stroke. International Journal of Molecular Sciences. 2020;21(18):6718.
48. Kawabori M, Shichinohe H, Kuroda S, Houkin K. Clinical trials of stem cell therapy for cerebral ischemic stroke. International Journal of Molecular Sciences. 2020;21(19):7380.
49. Achiron A, Dolev M, Menascu S, Zohar D-N, Dreyer-Alster S, Miron S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Multiple Sclerosis Journal. 2021:135245852110034.
50. Svensson J, Ghatnekar O, Lindgren A, Lindvall O, Norrving B, Persson U, et al. Societal value of stem cell therapy in stroke–a modeling study. Cerebrovascular Diseases. 2012;33(6):532-9.
51. Oh J, Lee J, Piao C, Jeong JH, Lee M. A self-assembled DNA-nanoparticle with a targeting peptide for hypoxia-inducible gene therapy of ischemic stroke. Biomaterials science. 2019;7(5):2174-90.
52. Hughes SM, Parr-Brownlie LC, Bosch-Bouju C, Schoderboeck L, Sizemore R, Abraham W. Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms. Frontiers in molecular neuroscience. 2015;8:14.
53. Lykken EA, Shyng C, Edwards RJ, Rozenberg A, Gray SJ. Recent progress and considerations for AAV gene therapies targeting the central nervous system. Journal of neurodevelopmental disorders. 2018;10(1):1-10.
54. Ge L-J, Yang F-H, Li W, Wang T, Lin Y, Feng J, et al. In vivo neuroregeneration to treat ischemic stroke through NeuroD1 AAV-based gene therapy in adult non-human primates. Frontiers in cell and developmental biology. 2020;8.
55. Ho JK, Borle K, Dragojlovic N, Dhillon M, Kitchin V, Kopac N, et al. Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review. PharmacoEconomics. 2021:1-25.
56. National Center for Chronic Disease Prevention and Health Promotion DfHDaSP. Stroke Facts: Centers for Disease Control and Prevention; 2021 [cited 2022 January 16]. Available from: https://www.cdc.gov/stroke/facts.htm.
57. Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. Journal of comparative effectiveness research. 2018;7(1):15-28.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
